British Society for Immunology - Annual Congress 2002: 3-6 December 2002, Harrogate, UK

TY - JOUR

T1 - British Society for Immunology - Annual Congress 2002: 3-6 December 2002, Harrogate, UK

AU - Klavinskis, L

PY - 2003/2/1

Y1 - 2003/2/1

N2 - This meeting reported on a number of new methods developed for breaking immune tolerance and generating robust immune responses to tumors, which were previously thought to be non-immunogenic. These findings have great therapeutic potential; at the cellular level, T-cell anergy induced by TGF[beta] could potentially be inhibited by upregulation of Smad7 in T-cells. Furthermore, cytotoxic T-cells could be raised to tumor antigens, and tumors can be eliminated by blocking the T-cell downregulatory surface marker CTLA-4 with antibodies. Finally, therapeutic levels of tumor-specific cytotoxic T-cells could be induced to non-immunogenic tumor antigens by targeting them to DCs; this was achieved by conjugating the tumor antigens to the CCR6 chemokine ligand HBD2

AB - This meeting reported on a number of new methods developed for breaking immune tolerance and generating robust immune responses to tumors, which were previously thought to be non-immunogenic. These findings have great therapeutic potential; at the cellular level, T-cell anergy induced by TGF[beta] could potentially be inhibited by upregulation of Smad7 in T-cells. Furthermore, cytotoxic T-cells could be raised to tumor antigens, and tumors can be eliminated by blocking the T-cell downregulatory surface marker CTLA-4 with antibodies. Finally, therapeutic levels of tumor-specific cytotoxic T-cells could be induced to non-immunogenic tumor antigens by targeting them to DCs; this was achieved by conjugating the tumor antigens to the CCR6 chemokine ligand HBD2

UR - http://www.scopus.com/inward/record.url?scp=0037295309&partnerID=8YFLogxK

M3 - Editorial

VL - 6

SP - 118

EP - 121

JO - IDRUGS

JF - IDRUGS

IS - 2

ER -